Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Adamis Pharmaceuticals Corp. (ADMP) is “One to Watch”

|Includes: Adamis Pharmaceuticals Corp. (ADMP)

Adamis Pharmaceuticals Corp., an emerging biopharmaceutical company, is combining specialty pharmaceuticals and biotechnology to create treatment options in the areas of allergy, respiratory, oncology, and immunological disorders as well as for infectious diseases. With novel products and breakthrough science, the company has positioned itself to become a leader in the biopharmaceutical industry.

The company’s current initiatives include the development of a prefilled single-dose epinephrine syringe for which a New Drug Application (NDA) has been submitted to the FDA. Adamis is also developing inhaled therapeutics for allergic rhinitis, asthma, and COPD under a December 2010 agreement with Beximco Pharmaceuticals Ltd., a Bangladesh conglomerate with over 400 products ranging from allergy to oncology.

Earlier this year, Adamis’ biotechnology unit completed the acquisition of a novel technology forming the basis for a prostate cancer vaccine called TeloB-VAX. This technology is scheduled to enter Phase II studies. The vaccine platform may also be able to treat other tumor types, such as lung, breast, and colon cancers, as well as viral diseases, including chronic hepatitis, human papilloma virus (HPV), and influenza.

Adamis is led by a management team that retains considerable expertise in biotechnology, immunology, cancer management, and pharmaceutical research and development, among other medical fields. Members of the team have accumulated experience in executive corporate leadership and financial roles, coming from companies such as Citigroup Global Markets Inc. and Merrill Lynch.

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net